ArticleMicrobiology spectrum2022
The Selection of Antibiotic- and Bacteriophage-Resistant Pseudomonas aeruginosa Is Prevented by Their Combination.
Article in Microbiology spectrum, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Codelivering Polymyxin B and Phage Using Thermosensitive Hydrogel for Treating Carbapenem-ResistantACS omega · 2026Article
- Advances in Ciprofloxacin Derivatives: Emerging Strategies to Combat Antimicrobial Resistance.Topics in current chemistry (Cham) · 2026Review
- Impact ofAntimicrobial agents and chemotherapy · 2026Article
- Three Novel Bacteriophages for the Biocontrol ofPathogens (Basel, Switzerland) · 2025Article
- Review
- Therapeutic Optimization ofViruses · 2025Article
- Adjunctive phage therapy improves antibiotic treatment of ventilator-associated-pneumonia with Pseudomonas aeruginosa.Nature communications · 2025Article
- Multi-strain phage induced clearance of bacterial infections.bioRxiv : the preprint server for biology · 2024Article
- Bacteriophage-Antibiotic Combination Therapy againstAntibiotics (Basel, Switzerland) · 2023Review
- Bacteriophages: The promising therapeutic approach for enhancing ciprofloxacin efficacy against bacterial infection.Journal of clinical laboratory analysis · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Bacteria developing resistance compromise the efficacy of antibiotics or bacteriophages (phages). We tested the association of these two antibacterials to circumvent resistance. With the Hollow Fiber Infection Model (HFIM), we mimicked the concentration profile of ciprofloxacin in the lungs of patients treated orally for Pseudomonas aeruginosa infections and, independently, mimicked a single inhaled administration of phages (one or two phages). Each treatment selects for antibiotic- or phage-resistant clones in less than 30 h. In contrast, no bacteria were recovered from the HFIM at 72 h when ciprofloxacin was started 4 h post phage administration, even when increasing the initial bacterial concentration by 1,000-fold. The combination of phages with antibiotics used according to clinical regimens prevents the growth of resistant clones, providing opportunities to downscale the use of multiple antibiotics.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.